Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

I don't doubt Dew's contention that NVS/MNTA strongly suggested they will launch at risk. Or perhaps they meant they strongly suspected they wouldn't have to, as Dew's previous message implies.

Technically, a launch is considered "at risk" if the Appellate Court has not yet ruled. So, if NVS/MNTA win the patent case in the District Court and then launch when the H-W stay expires in Feb 2017, it will still be considered "at risk" because TEVA will surely file an appeal.